Home ‹ African Swine Fever ‹ [Naturally attenuated candidates] : Development of a “naturally” attenuated vaccine that doesn’t persist or is excreted
African Swine Fever roadmap:
Vaccines

Roadmap for the development of a candidate vaccine for ASF

Download ASF Vaccine Roadmap

2

Naturally attenuated candidates

visit roadmap

Dependencies

  • 18 Challenge model

Next steps

Naturally attenuated candidates

Research Question

  • The development of a cross protective ASF vaccine by passage in tissue culture or a mutant low pathogenic wild type strain

Research Gaps and Challenges

  • Lack of cross protection among different isolates
  • Risk of reversion to virulence

Solution Routes

  • Perform passage in tissue culture to reduce virulence
  • Identify mutant low pathogenic wild strains

Dependencies

  • Identify strains that give greatest cross protection
  • Develop suitable cell lines for high titre propagation and licensing

State Of the Art

  • Experimentally, some level of homologous protection can be achieved by inoculation of pigs with low-virulence isolates obtained by passage in tissue culture or by deletion of genes involved in virulence, as well as low virulence isolates from the field
  • Challenge models have been evaluated and are available

Projects

What activities are planned or underway?

African Swine Fever virus inactivation by feed additives in vitro

Planned Completion date 01/01/2022

Source Countries:

NetherlandsIconNetherlands

The incursion risk of African swine fever for the Netherlands by human-mediated routes

Planned Completion date 01/01/2022

Source Countries:

NetherlandsIconNetherlands